In cancer patients, lower expression of sGSN in the TME correlates with patient survival, especially in subcohorts of patients with increased CLEC9A intratumoral expression and prevalence of mutations in proteins associated with actin cytoskeleton. The gene discussed is CLEC9A; the disease is cancer.